Literature DB >> 6801987

Variable expressivity of autosomal dominant anterior segment mesenchymal dysgenesis in six generations.

H M Hittner, F L Kretzer, J H Antoszyk, R E Ferrell, R S Mehta.   

Abstract

Of 58 members in a six-generation family with anterior segment mesenchymal dysgenesis with variable expressivity, 21 of 35 members (60%) at risk were affected. Of the 15 living affected family members, nine (60%) had visual acuities of 6/12 (20/40) or better in at least one eye, five (33%) had visual acuities between 6/15 and 6/60 (20/50 and 20/200) in at least one eye, and one (7%) had a visual acuity of less than counting fingers at one foot in both eyes. All nine affected patients who underwent slit-lamp examinations had corneal abnormalities with and without synechiae. All 15 affected patients also had cataracts, and three of the 15 (20%) had optic nerve abnormalities. In a corneal button from the severely affected proband, Descemet's layer and endothelial cells were absent even in the periphery. Other corneal and lenticular changes were secondary to the primary endothelial defect. Anterior segment mesenchymal dysgenesis in this family appeared to be caused by an aberration of the first wave of mesenchyme from the rim of the optic cup.

Entities:  

Mesh:

Year:  1982        PMID: 6801987     DOI: 10.1016/0002-9394(82)90700-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

Review 1.  Genetics of aniridia and anterior segment dysgenesis.

Authors:  A Churchill; A Booth
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

2.  Familial glaucoma iridogoniodysplasia maps to a 6p25 region implicated in primary congenital glaucoma and iridogoniodysgenesis anomaly.

Authors:  T Jordan; N Ebenezer; R Manners; J McGill; S Bhattacharya
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

Review 3.  Genetic modifiers as relevant biological variables of eye disorders.

Authors:  Kacie J Meyer; Michael G Anderson
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

4.  Atypical vitelliform macular dystrophy in a 5-generation family.

Authors:  H M Hittner; R E Ferrell; R P Borda; J Justice
Journal:  Br J Ophthalmol       Date:  1984-03       Impact factor: 4.638

5.  Anterior segment mesenchymal dysgenesis: probable linkage to the MNS blood group on chromosome 4.

Authors:  R E Ferrell; H M Hittner; F L Kretzer; J H Antoszyk
Journal:  Am J Hum Genet       Date:  1982-03       Impact factor: 11.025

6.  Heterogeneity in dominant anterior segment malformations.

Authors:  G E Holmström; W P Reardon; M Baraitser; J S Elston; D S Taylor
Journal:  Br J Ophthalmol       Date:  1991-10       Impact factor: 4.638

7.  Functional analysis of human mutations in homeodomain transcription factor PITX3.

Authors:  Satoru Sakazume; Elena Sorokina; Yoshiki Iwamoto; Elena V Semina
Journal:  BMC Mol Biol       Date:  2007-09-21       Impact factor: 2.946

8.  Surgical outcomes of Glaucoma associated with Axenfeld-Rieger syndrome.

Authors:  Emily M Zepeda; Kari Branham; Sayoko E Moroi; Brenda L Bohnsack
Journal:  BMC Ophthalmol       Date:  2020-05-01       Impact factor: 2.209

9.  Anterior segment mesenchymal dysgenesis in a large Australian family is associated with the recurrent 17 bp duplication in PITX3.

Authors:  Kim M Summers; Stephen J Withers; Glen A Gole; Sara Piras; Peter J Taylor
Journal:  Mol Vis       Date:  2008-11-05       Impact factor: 2.367

10.  FOXE3 contributes to Peters anomaly through transcriptional regulation of an autophagy-associated protein termed DNAJB1.

Authors:  Shahid Y Khan; Shivakumar Vasanth; Firoz Kabir; John D Gottsch; Arif O Khan; Raghothama Chaerkady; Mei-Chong W Lee; Carmen C Leitch; Zhiwei Ma; Julie Laux; Rafael Villasmil; Shaheen N Khan; Sheikh Riazuddin; Javed Akram; Robert N Cole; C Conover Talbot; Nader Pourmand; Norann A Zaghloul; J Fielding Hejtmancik; S Amer Riazuddin
Journal:  Nat Commun       Date:  2016-04-06       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.